A 4250

Drug Profile

A 4250

Alternative Names: A-4250

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albireo AB
  • Developer Albireo AB; Albireo Pharma
  • Class Antipruritics
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis; Intrahepatic cholestasis; Alagille syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intrahepatic cholestasis; Primary biliary cirrhosis; Pruritus
  • Phase I Alagille syndrome
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 16 May 2017 Albireo Pharma plans a phase III trial along with an open label extension study for Progressive familial intrahepatic cholestasis, in the US, Canada, western Europe, the Middle East and Australia by the end of 2017
  • 16 May 2017 Albireo Pharma has patent protection for the composition of matter and a method of use of A 4250 in Europe, Japan and World
  • 16 May 2017 Albireo Pharma receives patent allowance for the method of treatment for A 4250 for progressive familial intrahepatic cholestasis, non-alcoholic steatohepatitis and other liver diseases in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top